MaxCyte (MXCT) Projected to Post Earnings on Tuesday

MaxCyte (NASDAQ:MXCT) is anticipated to release its Q4 2025 results after the market closes on Tuesday, March 24th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $9.1580 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:30 PM ET.

MaxCyte Stock Performance

NASDAQ MXCT opened at $0.81 on Tuesday. The company has a market cap of $86.51 million, a PE ratio of -1.84 and a beta of 1.22. The firm’s 50 day moving average price is $0.96 and its 200-day moving average price is $1.35. MaxCyte has a 52-week low of $0.64 and a 52-week high of $3.33.

Wall Street Analysts Forecast Growth

MXCT has been the subject of several research analyst reports. Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a research report on Sunday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, MaxCyte currently has an average rating of “Hold” and an average price target of $6.00.

Hedge Funds Weigh In On MaxCyte

Several large investors have recently made changes to their positions in MXCT. Prudential Financial Inc. acquired a new stake in shares of MaxCyte during the 2nd quarter valued at about $26,000. State of Wyoming acquired a new position in MaxCyte in the 2nd quarter worth about $38,000. BNP Paribas Financial Markets raised its holdings in MaxCyte by 266.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock worth $57,000 after purchasing an additional 18,913 shares during the period. Jain Global LLC purchased a new position in MaxCyte during the fourth quarter worth approximately $45,000. Finally, Virtu Financial LLC purchased a new position in MaxCyte during the fourth quarter worth approximately $67,000. 68.81% of the stock is currently owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.